Choroidal thickness as a possible predictor of non-response to intravitreal bevacizumab for macular edema after retinal vein occlusion.
Journal
Scientific reports
ISSN: 2045-2322
Titre abrégé: Sci Rep
Pays: England
ID NLM: 101563288
Informations de publication
Date de publication:
09 01 2023
09 01 2023
Historique:
received:
02
08
2022
accepted:
06
01
2023
entrez:
9
1
2023
pubmed:
10
1
2023
medline:
12
1
2023
Statut:
epublish
Résumé
To evaluate outcomes of intravitreal bevacizumab (IVB) treating macular edema (ME) after retinal vein occlusion (RVO) following pro re nata (PRN) regimen and investigate potential predictors of non-response. Retrospective analysis of 126 treatment-naive eyes with ME after RVO. Eyes were treated initially with IVB of 1.25 mg/ml. Therapy was switched in case of non-response. Outcome measures included best-corrected visual acuity (BCVA) and central macular thickness (CMT), which were recorded over 4 years of treatment. BCVA improved significantly during first 2 years. CMT decreased significantly during the 4-year follow-up period. Switching was required in 42 eyes (33%). 34 eyes (26.9%) were switched to steroids, while 8 eyes (6.3%) were switched to other anti-VEGF due to diagnosed glaucoma. Switching occurred after 12.4 ± 8.3 months and an average of 8 ± 4.1 IVBs. Compared with the treatment-responsive group, the treatment-unresponsive group had significantly worse BCVA, higher CMT and subfoveal choroidal thickness (SFCT) at baseline. Treatment IVB following PRN regimen showed significant functional and anatomic improvement in patients with ME after RVO. Switching was required in more than one third of eyes. Higher baseline SFCT could be considered as predictor for non-response to such therapy and thus an indicator of early switching.
Identifiants
pubmed: 36624124
doi: 10.1038/s41598-023-27753-7
pii: 10.1038/s41598-023-27753-7
pmc: PMC9829912
doi:
Substances chimiques
Bevacizumab
2S9ZZM9Q9V
Angiogenesis Inhibitors
0
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
451Informations de copyright
© 2023. The Author(s).
Références
BMC Ophthalmol. 2019 Jun 21;19(1):133
pubmed: 31226968
Int Ophthalmol. 2019 May;39(5):1061-1069
pubmed: 29605881
Asia Pac J Ophthalmol (Phila). 2017 Nov-Dec;6(6):546-553
pubmed: 29204993
Ophthalmology. 1995 Oct;102(10):1434-44
pubmed: 9097789
Ophthalmologe. 2020 Jan;117(1):50-57
pubmed: 31098660
Ophthalmologica. 2015;234(2):109-18
pubmed: 26305536
Eur J Ophthalmol. 2016 Nov 4;26(6):627-632
pubmed: 26847213
Am J Ophthalmol. 2012 Feb;153(2):196-203.e1
pubmed: 22264942
Arch Ophthalmol. 1996 Oct;114(10):1243-7
pubmed: 8859084
Indian J Ophthalmol. 1994 Sep;42(3):109-32
pubmed: 7829175
J Thromb Haemost. 2010 Sep;8(9):1886-94
pubmed: 20492457
Eye (Lond). 2013 Jun;27(6):688-97
pubmed: 23470793
Br J Ophthalmol. 2021 May;105(5):704-710
pubmed: 32620686
Retina. 2016 Dec;36(12):2297-2303
pubmed: 27870799
Eur J Ophthalmol. 2012 Nov-Dec;22(6):992-1000
pubmed: 22865404
Emerg Infect Dis. 2015 Jan;21(1):171-3
pubmed: 25531168
Int J Ophthalmol. 2016 May 18;9(5):725-9
pubmed: 27275430
Ophthalmology. 2011 Dec;118(12):2453-60
pubmed: 21764136
Invest Ophthalmol Vis Sci. 2009 Mar;50(3):1025-32
pubmed: 19060280
Graefes Arch Clin Exp Ophthalmol. 2011 Feb;249(2):193-200
pubmed: 21337043
Br J Ophthalmol. 2014 Mar;98(3):339-44
pubmed: 24288389
Ophthalmology. 2011 Oct;118(10):2041-9
pubmed: 21715011
Retina. 2018 Mar;38(3):550-558
pubmed: 28234806
Graefes Arch Clin Exp Ophthalmol. 2010 Feb;248(2):155-9
pubmed: 19763601
Graefes Arch Clin Exp Ophthalmol. 2010 Nov;248(11):1567-72
pubmed: 20596719
BMJ. 2012 May 01;344:e3012
pubmed: 22549057
Am J Ophthalmol. 2012 Feb;153(2):204-208.e1
pubmed: 22264943
Am J Ophthalmol. 2013 Sep;156(3):543-547.e1
pubmed: 23688711
Sci Rep. 2021 Oct 6;11(1):19854
pubmed: 34615888
Ophthalmology. 2014 Jan;121(1):202-208
pubmed: 24084497
Expert Rev Clin Pharmacol. 2018 Sep;11(9):903-916
pubmed: 30071180
Trans Am Ophthalmol Soc. 2000;98:133-41; discussion 141-3
pubmed: 11190017
Br J Ophthalmol. 2019 Jan;103(1):55-59
pubmed: 29567791
Am J Ophthalmol. 2016 May;165:88-93
pubmed: 26944277
Ophthalmologe. 2021 Aug;118(8):865-878
pubmed: 33900429
Am J Ophthalmol. 2013 Mar;155(3):429-437.e7
pubmed: 23218699
Asia Pac J Ophthalmol (Phila). 2018 Jan-Feb;7(1):40-45
pubmed: 29280368
Retina. 2013 Sep;33(8):1659-72
pubmed: 23751942
Retina. 2017 Jul;37(7):1345-1351
pubmed: 27806001
N Engl J Med. 2010 Nov 25;363(22):2135-44
pubmed: 21105795
Thromb Haemost. 2021 Oct;121(10):1361-1366
pubmed: 33706397
Curr Eye Res. 2008 Feb;33(2):111-31
pubmed: 18293182
Ophthalmology. 2014 Jan;121(1):209-219
pubmed: 24112944
J Ophthalmol. 2014;2014:724780
pubmed: 25009743
PLoS One. 2009 Dec 04;4(12):e8158
pubmed: 19997642
Retina. 2013 May;33(5):901-10
pubmed: 23609064
Eur J Ophthalmol. 2012 Nov-Dec;22(6):1013-8
pubmed: 22569812
Eye (Lond). 2022 Jun;36(6):1194-1201
pubmed: 34117379
Eye (Lond). 2019 Jan;33(1):14-33
pubmed: 29995841
Retina. 2020 Jan;40(1):75-79
pubmed: 30308561
Clin Ophthalmol. 2010 Jul 30;4:809-16
pubmed: 20689798
Int J Ophthalmol. 2016 Jul 18;9(7):999-1005
pubmed: 27500108
Invest Ophthalmol Vis Sci. 2016 Sep 1;57(11):4679-85
pubmed: 27583829
Ophthalmology. 2012 Apr;119(4):802-9
pubmed: 22301066
Curr Drug Targets. 2016;17(3):328-36
pubmed: 26073857
Eur J Ophthalmol. 2014 Nov-Dec;24(6):897-903
pubmed: 25044137
Graefes Arch Clin Exp Ophthalmol. 2008 Sep;246(9):1241-7
pubmed: 18546006